X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA WYETH LTD NATCO PHARMA/
WYETH LTD
 
P/E (TTM) x 30.5 27.7 109.9% View Chart
P/BV x 23.1 5.3 431.3% View Chart
Dividend Yield % 0.5 1.3 38.9%  

Financials

 NATCO PHARMA   WYETH LTD
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
WYETH LTD
Mar-13
NATCO PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs8771,044 84.0%   
Low Rs424818 51.8%   
Sales per share (Unadj.) Rs223.4298.6 74.8%  
Earnings per share (Unadj.) Rs31.157.2 54.3%  
Cash flow per share (Unadj.) Rs40.358.4 68.9%  
Dividends per share (Unadj.) Rs5.0017.00 29.4%  
Dividend yield (eoy) %0.81.8 42.1%  
Book value per share (Unadj.) Rs219.5249.5 88.0%  
Shares outstanding (eoy) m33.0722.72 145.6%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.1 93.3%   
Avg P/E ratio x20.916.3 128.7%  
P/CF ratio (eoy) x16.115.9 101.3%  
Price / Book Value ratio x3.03.7 79.4%  
Dividend payout %16.129.7 54.2%   
Avg Mkt Cap Rs m21,50421,157 101.6%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m1,128400 281.9%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m7,3896,783 108.9%  
Other income Rs m167353 47.4%   
Total revenues Rs m7,5567,136 105.9%   
Gross profit Rs m1,7931,617 110.9%  
Depreciation Rs m30427 1,144.4%   
Interest Rs m3666 6,658.2%   
Profit before tax Rs m1,2901,938 66.6%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m309632 48.8%   
Profit after tax Rs m1,0271,301 79.0%  
Gross profit margin %24.323.8 101.8%  
Effective tax rate %23.932.6 73.4%   
Net profit margin %13.919.2 72.5%  
BALANCE SHEET DATA
Current assets Rs m3,6816,984 52.7%   
Current liabilities Rs m3,1232,056 151.9%   
Net working cap to sales %7.672.6 10.4%  
Current ratio x1.23.4 34.7%  
Inventory Days Days8999 90.1%  
Debtors Days Days5924 245.1%  
Net fixed assets Rs m7,685244 3,145.8%   
Share capital Rs m331227 145.6%   
"Free" reserves Rs m6,6705,441 122.6%   
Net worth Rs m7,2595,668 128.1%   
Long term debt Rs m95525 3,819.6%   
Total assets Rs m11,9577,901 151.3%  
Interest coverage x4.5353.3 1.3%   
Debt to equity ratio x0.10 2,982.5%  
Sales to assets ratio x0.60.9 72.0%   
Return on assets %11.716.5 70.5%  
Return on equity %14.222.9 61.7%  
Return on capital %20.734.0 60.9%  
Exports to sales %39.40.2 18,037.3%   
Imports to sales %5.736.3 15.7%   
Exports (fob) Rs m2,90815 19,647.3%   
Imports (cif) Rs m4212,465 17.1%   
Fx inflow Rs m3,44515 22,667.1%   
Fx outflow Rs m7032,677 26.3%   
Net fx Rs m2,743-2,662 -103.0%   
CASH FLOW
From Operations Rs m1,440923 156.0%  
From Investments Rs m-1,089317 -343.7%  
From Financial Activity Rs m-353-481 73.3%  
Net Cashflow Rs m-1759 -0.2%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 51.1 2.9%  
Indian inst/Mut Fund % 7.8 11.3 69.4%  
FIIs % 16.6 7.2 231.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 30.4 85.5%  
Shareholders   25,395 21,978 115.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   ALEMBIC LTD  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SUN PHARMA  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jan 22, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS